M. Scott Perry – Dravet Syndrome

Access Program Information

<p>This is an expanded access use of <strong>Stiripentol</strong> in <em>Dravet Syndrome</em> or <em>epileptic encephalopathies associated with sodium channel mutations (SCN1A Mutations)</em> who have failed other drugs in an effort to give them the best chance at seizure control and quality of life. As a treatment protocol and not a research study, children will only be monitored on a clinical basis for seizure improvement and side effects predominantly by parent and caregiver report.</p>

Rare Disease: